SCI时时刷

search
AKR1C4 regulates the sensitivity of colorectal cancer cells to chemotherapy through ferroptosis modulation
AKR1C4 regulates the sensitivity of colorectal cancer cells to chemotherapy through ferroptosis modulation
Colorectal cancer (CRC) remains a major global health concern, necessitating innovative therapeutic strategies to enhance ...
Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial
Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial
TLD-1 is a novel pegylated liposomal doxorubicin (PLD) formulation aiming to optimise the PLD efficacy-toxicity ratio. We ...
Comparable efficacy of oral bendamustine versus intravenous administration in treating hematologic malignancies
Comparable efficacy of oral bendamustine versus intravenous administration in treating hematologic malignancies
The purpose of this study was to analyze potential differences in antitumor efficacy and pharmacokinetics between intraven...
ZNF384 transcriptionally activated MGST1 to confer TMZ resistance of glioma cells by negatively regulating ferroptosis
ZNF384 transcriptionally activated MGST1 to confer TMZ resistance of glioma cells by negatively regulating ferroptosis
Drug resistance is one of the major reasons of the poor prognosis and recurs frequently in glioma. Ferroptosis is consider...
Pre-treatment amino acids and risk of paclitaxel-induced peripheral neuropathy in SWOG S0221
Pre-treatment amino acids and risk of paclitaxel-induced peripheral neuropathy in SWOG S0221
Chemotherapy-induced peripheral neuropathy (CIPN) is a treatment-limiting and debilitating neurotoxicity of many commonly ...
Oral docetaxel plus encequidar – a phase 1 clinical trial
Oral docetaxel plus encequidar – a phase 1 clinical trial
To determine the bioavailability, safety, and tolerability of a single dose of oral docetaxel plus encequidar (oDox ...
Using maximum plasma concentration (Cmax) to personalize taxane treatment and reduce toxicity
Using maximum plasma concentration (Cmax) to personalize taxane treatment and reduce toxicity
Taxanes are a widely used class of anticancer agents that play a vital role in the treatment of a variety of cancers. Howe...
Non-linear IV pharmacokinetics of the ATR inhibitor berzosertib (M6620) in mice
Non-linear IV pharmacokinetics of the ATR inhibitor berzosertib (M6620) in mice
The Ataxia Telangiectasia and Rad3-related (ATR) protein complex is an apical initiator of DNA damage response pathways. S...
Combined treatment of All-trans retinoic acid with Tamoxifen suppresses ovarian cancer
Combined treatment of All-trans retinoic acid with Tamoxifen suppresses ovarian cancer
Ovarian cancer is a malignant tumor of the female reproductive system, and its mortality rate is as high as 70%. Estrogen ...
Preventive effect of free radical scavenger edaravone lotion on cyclophosphamide chemotherapy-induced alopecia
Preventive effect of free radical scavenger edaravone lotion on cyclophosphamide chemotherapy-induced alopecia
We investigated the inhibitory effect of edaravone (EDR) lotion on chemotherapy-induced alopecia (CIA) to improve the qual...
Pharmacokinetic study of capivasertib and the CYP3A4 substrate midazolam in patients with advanced solid tumors
Pharmacokinetic study of capivasertib and the CYP3A4 substrate midazolam in patients with advanced solid tumors
Capivasertib, a potent, selective inhibitor of all three AKT serine/threonine kinase (AKT) isoforms, is being evaluated in...
PARP1 promotes EGFR-TKI drug-resistance via PI3K/AKT pathway in non-small-cell lung cancer
PARP1 promotes EGFR-TKI drug-resistance via PI3K/AKT pathway in non-small-cell lung cancer
Tyrosine kinase inhibitor (TKI) resistance is the main type of drug resistance in lung cancer patients with epidermal grow...
A polo-like kinase 1 inhibitor enhances erastin sensitivity in head and neck squamous cell carcinoma cells in vitro
A polo-like kinase 1 inhibitor enhances erastin sensitivity in head and neck squamous cell carcinoma cells in vitro
Polo-like kinase 1 (PLK1) is a critical therapeutic target in the treatment of head and neck squamous cell carcinoma (HNSC...
Pharmacology and pharmacokinetics of tazemetostat
Pharmacology and pharmacokinetics of tazemetostat
Tazemetostat, a novel oral selective inhibitor of enhancer of zeste homolog 2 (EZH2), was approved by the Food and Drug Ad...
Postoperative chemotherapy relative dose intensity and overall survival in patients with colon cancer
Postoperative chemotherapy relative dose intensity and overall survival in patients with colon cancer
Quantifying the association of chemotherapy relative dose intensity (RDI) with overall survival may enable supportive care...
Phase 2 study of glucarpidase in patients with delayed methotrexate elimination after high-dose methotrexate therapy
Phase 2 study of glucarpidase in patients with delayed methotrexate elimination after high-dose methotrexate therapy
High-dose methotrexate therapy (HD-MTX) is a standard treatment for various malignant tumors, but approximately 1–10...
Pharmacokinetic and bioequivalence study of two capecitabine tablets in Chinese patients with solid tumor cancer
Pharmacokinetic and bioequivalence study of two capecitabine tablets in Chinese patients with solid tumor cancer
Capecitabine (CAP) is one of the fluoropyrimidine deoxynucleoside carbamates, which can be converted to 5-fluorouracil (5-...